Telix announces cardinal health as u.s. commercial distributor for zircaix®

Melbourne, australia, sept. 17, 2024 (globe newswire) -- telix pharmaceuticals limited (asx: tlx, telix, the company) today announces that it has selected cardinal health, inc. (nyse: cah, cardinal health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its pet1 agent, zircaix®2 (tlx250-cdx) for the imaging of kidney cancer in the united states (u.s.), subject to regulatory approval.
CAH Ratings Summary
CAH Quant Ranking